AVIR
Atea Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.33
+1.33%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.26
From 52W high−13.33%
Volume591558.00
Market cap$427.49M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$5.26
From 52W high
−13.33%
Volume
591558.00
Market cap
$427.49M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
P/E (TTM)
—
RSI (14)
48.2
MomentumView details →
1D Return
+1.33%
YTD Return
+46.92%
SummaryUpdated Jun 1, 2026
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Boston, Massachusetts. The company went public in October 2020 and focuses on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Atea has transitioned from a multi-program antiviral company to primarily focusing on two key therapeutic areas: COVID-19 treatment and hepatitis C virus (HCV) treatment, after deprioritizing its dengue fever program in 2022 due to clinical development challenges.
Similar companies
Latest newsMore news →
Atea Pharmaceuticals, Inc. held its Q2 2026 earnings call on August 12, 2026.39d agoAtea Pharmaceuticals reported that its Phase 3 C-BEYOND trial of BEM/RZR for hepatitis C met primary and secondary endpoints, supporting a potential best-in-class profile.39d agoAtea Pharmaceuticals announced that its Bemnifosbuvir/Ruzasvir met primary and secondary endpoints in the Phase 3 C-BEYOND North America trial for hepatitis C virus treatment.54d ago